Multimodality Therapy of Cancer: Solid Tumour Treatment is a Team Sport! Principles of Surgery 2011 Andy Smith, MD Department of Surgery University of.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Neoadjuvant therapy for Rectal cancer
Diagnosis.
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Endoscopic Ultrasound in Rectal Cancer Natasha Schneider November 15, 2010.
AJCC Staging Moments AJCC TNM Staging 7th Edition Rectal Case #3 Contributors: J. Milburn Jessup, MD Cancer Diagnosis Program, DCTD, NCI, Rockville, Maryland.
Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.
Rectal Cancer: A Complete Clinical Response…Now what?
A COMPARISON of LAPAROSCOPICALLY ASSISTED and OPEN COLECTOMY for COLON CANCER The Clinical Outcomes of Surgical Therapy Study Group (Cost Study) NEJM,
JHSGR Neoadjuvant Therapy For Rectal Cancer Dr Chris TL Cheng Princess Margaret Hospital.
National Oesophago–Gastric Cancer Audit Comparing local and national figures.
SURGICAL APPROACH TO GYNAECOLOGICAL CANCERS
Colon Cancer Basic Science 9/21/05. Colon and rectal neoplasms are characterized by: Consist of the third most common site of new cancer cases and deaths.
First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.
How to get more nodes in laparoscopic colon surgery John Marks MD Chief Division of Colorectal Surgery Lankenau Hospital and Institute of Medical Research.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Guidance on Cancer Services Improving Outcomes for People with Skin Tumours including Melanoma NICE Stateholder Consultation version July 2005.
CRITICAL READING OF THE LITERATURE RELEVANT POINTS: - End points (including the one used for sample size) - Surrogate end points - Quality of the performed.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
AJCC TNM Staging 7th Edition Breast Case #3
Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease Jose G. Guillem, MD, MPH Department of Surgery.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Treatment of Early Malignant Rectal Polyp
A REVISIT TO MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOUR (GIST) Joint Hospital Surgical Grand Round 17 Jan 2015 Grace Liu Pamela Youde Nethersole Eastern.
Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.
Slawomir Marecik, MD, FACS Advocate Lutheran General Hospital, Park Ridge, IL Clinical Assistant Professor University of Illinois, Chicago, USA.
Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.
Eleni Galani Medical Oncologist
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
Brendan Moran Basingstoke OCTOBER 2008
Role of EUS in colon lesions Pietro Fusaroli Gastroenterologia Università di Bologna.
T4 Colon Cancer and Laparoscopic Approach Gustavo Plasencia MD FACS, FASCRS Clinical Professor of Surgery Gustavo Plasencia MD FACS, FASCRS Clinical Professor.
What is the Preferable Treatment Option for T1/T2 Low Rectal Cancer? Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology.
1 Recent trends in colorectal cancer in Norway: incidence, management and outcomes Arne Wibe, MD, PhD Professor of Surgery St. Olavs Hospital Trondheim,
The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena
Quality in Cancer Surgery Dr. Craig McFadyen VP Cancer Services, Grand River Hospital Regional VP (Waterloo-Wellington), Cancer Care Ontario Medical Director.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Accuracy of EUS in diagnosis of rectal cancer KKUH experience
Local recurrence after rectal cancer resection is strongly related to the plane of surgical (PoS) dissection and is further reduced by pre-operative short.
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
Management of Recurrent and Advanced Tumours: When are Tumours Resectable, and Multidisciplinary Management Dr. Andrew McFadden Surgical Oncology.
Gastric Cancer Resections in BC: How are we doing? Trevor D Hamilton MD FRCSC Surgical Oncology Network November 7, 2015.
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Mamoun A. Rahman Surgical SHO Mr Osborne’s team. Introduction Blood transfusion: -Preoperative ( elective) -Intra/postoperative ( urgent) Blood transfusion.
Introduction to Tumor Board
Radical surgery is the preferable treatment option for T1- 2/N0 low rectal cancer Jose G. Guillem, MD, MPH Department of Surgery Memorial Sloan Kettering.
Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.
Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research “ Rectal cancer radiotherapy – why do we give it and how do we do it?”
Basingstoke Colorectal The Particular Problem of Low Rectal Cancer Brendan Moran Basingstoke 4 th East-West Colorectal Days Hungary 2008.
Role of MRI in Primary Rectal Cancer Staging and Management
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.
Assessing Quality of Pathology Reporting: The Case of Tongue Cancer Lihua Liu 1, PhD Wesley Y. Naritoku 2, MD, PhD Juanjuan Zhang 1, MS Lenard Berglund.
RECTAL CARCINOMA AND PREOPERATIVE MRI: USING A NATIONAL DATASET FOR REGIONAL AUDIT South West Cancer Intelligence Service J Weeks
Overview: Breast Cancer- Surgical Treatment
Laparoscopic surgery for rectal cancer What is the evidence?
Karcinom rektuma- management
Indications for Breast MR Imaging
Joint Hospital Surgical Grand Round Dr Stewart Chan Kwong Wah Hospital
Department of General Surgery, Upper Gastrointestinal Unit,
Erica V. Bloomquist, MD Heather Wright, MD
Dr Jessica Jenkins Consultant Oncologist
Effect of Neoadjuvant Concurrent Chemoradiotherapy on Locally Advanced Middle and Low Rectal Cancer— A Propensity Score Matching Study 官泰全,林春吉,楊純豪,姜正愷,林宏鑫,藍苑慈,
The STAR-TREC Trial SIV Presentation
Changes in TNM 8 To be used from
Presentation transcript:

Multimodality Therapy of Cancer: Solid Tumour Treatment is a Team Sport! Principles of Surgery 2011 Andy Smith, MD Department of Surgery University of Toronto

Overview Don’t just whack it out! Optimal care requires multiple disciplines How do we accomplish multidisciplinary care in Ontario?

Colorectal Cancer #2 cancer killer in Canada Nearly all CRC patients see a surgeon –4/5 patients present with “curable” disease –1/3 will develop metastatic disease Optimal care happens only when there is coordinated involvement of multiple professionals –including radiology

How does rectal cancer attack? 1.Longitudinal growth 2.Circumferential growth 3.Focus on the “tube” and the surrounding “fat packet” (mesorectum) 4.Suboptimal management can happen in or out of the OR

Rectal Cancer Cure Requires….. Adam et al Role of circumferential margin involvement in local recurrence of rectal cancer. Lancet 1994; 344:707-11

How do we get R0? Accurate staging (MRI, ERUS) Appropriate application of preoperative chemotherapy and radiotherapy Precision surgery –Sharp anatomic dissection Assessment of the quality of the excision and patient outcomes –Pathological audit and feedback –Oncologic & Functional outcomes

Pre-operative Staging and Treatment Planning The radiologist

Is the tumour locally advanced? There is a large mass measuring 8.7 x 7.2 cm, which invades the hepatic flexure, the pylorus, and the first and second portions of the duodenum. The epicenter appears to be the colon. There is no sign of bowel or gastric obstruction. There are small lymph nodes in the mesentery adjacent to the ascending colon measuring up to 1 cm. There are multiple small mesenteric lymph nodes measuring up to 9 mm. No definite invasion of the pancreas. The mass abuts the liver at the porta and the undersurface of segment 5, no definite invasion.

Conundrum This tumour is stuck to the bladder. Can I ‘get away’ with ‘cracking the tumour off’ the adjacent organ? It’s probably just inflammation, right?

Malignant adhesions present in % of tumours A surgeon cannot reliably tell which adhesions are malignant before resection Attachment to Contiguous Organs Inflammatory Adhesions Malignant Adhesions Does the CRC invade the adjacent organ?

Principle of Surgery Ideally, locally advanced adherent tumours should be diagnosed preoperatively through appropriate application of cross-sectional imaging, especially CT scanning, and should be assumed to be malignant in curative-intent operations.

Is it a T3/T4 or node positive? Accurate staging informs need for pre- operative treatment CT scan gives a “sense” for extent of tumour MRI and/or ERUS are better CRT

Appropriate Preoperative Therapy The radiation oncologist and medical oncologists

Case example 61M two months history of bright red blood per rectum digital rectal examination –posterior midline is a firm and possibly fixed rectal cancer –suspect this is at least a T3 tumor –located 1 cm above the top of the sphincter muscle –tone, squeeze and sensation are all normal

CT and MRI

Principle of Surgery Consider neoadjuvant therapy –Radiation therapy helps! Meta-analyses on rectal cancer –Pre-operative radiation improves local control and overall survival1,2 +/- chemotherapy 1.JAMA 2000;284: Lancet 2001; 358:1291

Key excerpt from the CCO guideline All rectal cancers should undergo preoperative workup to assess the extent to which the CRM is threatened. This includes pelvic CT or MRI. For lesions that are stage II (i.e., T3 or T4) or III (i.e., likely positive lymph nodes on cross sectional imaging), neoadjuvant therapy should be considered. Such determinations demand a high-quality MRI and, ideally for T status, a trans-rectal ultrasound

Precision Surgery The Surgeon

Total Mesorectal Excision (TME) Key focus on: –radial resection margin –extent of distal mesorectal excision Advantages –lower recurrence rates –lower stoma rates –decreased nerve damage

TME reduces local recurrence of rectal cancer TME technique impacts margin status Reduce LR from 25-30% (blunt) to 10 to 15% (TME)1 “Single digit” rates of LR reported from large, speciality units with TME only 1. Havenga, Enker et al Eur J Surg Onc 1999

Validation of Quality Operation Shiny Visceral Mesorectal Fascia

1.Quality of surgery is a crucial determinant of outcome 2.Local recurrence = local residual = our failure… –To achieve clear margins –To preserve an intact mesorectum Principle of Surgery

Specimen quality is related to outcome 130 pts ( ) curative TME resections Mesorectum graded: 1. little bulk, defects down to muscularis propria 2. moderate bulk, irregular surface, no visible muscle 3. intact, smooth, no defect >5mm CRM+ve in only 7% –No relationship to LR, OR –Associated with grade 1 mesorectum MR grade Total patients Local recurrence Overall recurrence 1177(41%)10(59%) 2523(5.7%)9(17%) 3611(1.6%) p MR grade vs Recurrence Maslekar S, et al. Dis Colon Rectum 2007;50:

Staging and Adjuvant Therapy Decisions Pathology and Medical Oncology

Staging CRC is important How many lymph nodes do you need to accurately assess the nodal stage of a CRC patient (N-stage)?

Lymph Nodes and Treatment single most important factor for determining benefit from post-operative adjuvant chemotherapy in colon cancer clear benefit for “stage III” – node positive patients no clear benefit for “stage II” – node negative patients

What “benefits” are we talking about? in NODE POSITIVE patients: –15% absolute improvement in 5 year overall survival –30% absolute improvement in 5 year disease free survival perspective: this represents the biggest “bang for the buck” in adjuvant chemotherapy

The minimum number of lymph nodes that should be assessed is: CCO Guideline JSO 2010

Lymph Node Assessment and Patient Survival Caplin et al. Cancer 1998:83; 666 Law et al. J Surg Onc 2003:84;120

CRC Lymph Node Assessment is important! JNCI 2007 The number of lymph nodes resected was positively associated with survival for stage II and III CRC –16 of 17 studies Data support lymph node assessment as a quality marker in CRC care

The “Gap” 5% nodal harvest not stated 4% no nodes recovered Median nodal recovery = 8 nodes Only 27% had 12 or more nodes recovered Wright Ann Surg Onc 2003; 10:903-9

Principle of Surgery: It’s a Team Sport!

Compliance with Lymph Node Retrieval Guideline – Ontario Data

Lymph Node Talk – Dr A Smith -Evidence on 12 nodes -Importance of Pathology and Surgery working together -Clinical implications to patients -Visual Aids supplied to Labs (Dr Smith) -Intro of special techniques (e.g LN revealing solution) -Increased dialogue between Pathologists and Surgeons Support from RVP of CRRCC and hospital to secure resources for Pathology Assistants -Pathology Assistants joining team -Less variability in dissection techniques -Pathology Assistants examining ALL cancer specimens Up to Nov 7, 05 Sept 13, 04

Main Message CRC lymph node assessment/staging is increasingly relevant to surgeons “Homegrown” solutions are integral part of Quality improvement –Teamwork is essential Staging is becoming more precise

How do we “do” multidisciplinary care in Ontario? Evidence based guidelines generated in Ontario Audit and feedback Multidisciplinary Case Conferences –Tumour Boards

Optimization of surgical and pathological quality performance in radical surgery for colon and rectal cancer: Lymph nodes and margins Smith AJ, Driman DK, Spithoff K, McLeod R, Hunter A, Rumble RB, Langer B, and the Expert Panel on Colon and Rectal Cancer Surgery and Pathology A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

CRC cure requires R0 excision In-continuity multivisceral resection is required to achieve R0 (negative margin) resection 1 Poor results if adherent organs “chipped off” 2,3 –local recurrence: 69% vs. 18% –5 yr survival: 17% vs. 49% 1.Lehnert et al. Annals of Surgery Hunter et al. Am J Surg Gall et al. DCR. 1987

Optimization of surgical and pathological quality performance in radical surgery for colon and rectal cancer: Lymph nodes and margins A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Population-based Assessment of the Surgical Management of Locally Advanced Colorectal Cancer Govindarajan A, Coburn N, Kiss A, Rabeneck L, Smith AJ, Law CHL JNCI 2006

Multidisciplinary Cancer Conferences: Implications for rectal cancer management

Multidisciplinary Cancer Conference (MCC) Regularly scheduled meeting where representatives from surgery, medical oncology, radiation oncology, nursing, pathology, and diagnostic imaging discuss all appropriate diagnostic tests and suitable treatment options for an individual cancer patient (CCO 2006) Definitions

“Shouldn’t you use Chemotherapy first?”

Multidisciplinary Cancer Conferences 7-43% of the time after a patient’s case is discussed at MCC - the treatment plan will change (Chang 2001, Santoso 2004) 66-95% of all MCC recommendations are followed (Scholnik 1986, Petty 2002, Lutterbach 2005)

MCC - Where in the world? UK –After 1995 Calman-Hine report advocating MD care US –Required for accreditation by ACS, Commission on Cancer (50 years) Australia – National Demonstration Project using breast cancer

Ontario Tumor Boards: Standards A working conference: –usually weekly; ≥ 2/month –≥ 1 hour –All new and recurrent cancer cases referred Disciplines (in person or video-link): –surgery, rad onc, med onc, pathology, radiology, nursing, (± pharmacist, social services, genetics, nutrition, pastoral care…) Chair (coordinator): –Selects cases for detailed discussion –Reports to the head of the Cancer program Physicians: –Commit to attend and send cases –Responsible for discussing with the patient, making the recommendations and documenting in the medical record Wright FC, et al. 2007

CCO Standards Primary Function – Ensure all appropriate tests, treatment options and most appropriate treatment recommendations are generated for each cancer patient MCC Cases –Discussion at discretion of presenting physician, MCC chair

Conclusions The idea that the process and structure of health care can improve patient outcomes is tantalizing Very suggestive evidence of benefit Optimal care - certainly to discuss a patient’s treatment plan in a multidisciplinary forum

Questions?